Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study - The Lancet Oncology
COOP Champions: Martin Gasser, Senior Programme Officer at the Sustainable Enterprises and Economies Programme at the ITCILO Turin